Homepage-4

A New Path to Drug Discovery

Bi-XDC enables currently undruggable molecules and targets to become druggable. They are designed to address significant unmet medical needs in cancer and beyond.

Coherent Biopharma

a company pioneering and developing Bi-targeting XDC technology

15

Proprietary Technology

1 Proprietary Platform Technology
5+ First-in-Class Assets
15+
 Global IP Protection

110

Experienced Team

5+ Top scientists & industry experts. 110+ Experts professionals.

25

Solid Portfolio

5 Potential First-in-Class
10+ Products
10+ Oncology Indication Clinical Trials

3

Global Operation

Integrated management organization in China, the U.S and Australia.

Breaking News